Spyre Therapeutics (SYRE) financial statements
Spyre Therapeutics reported revenue of $0 in fiscal 2025, down 21.0% a year over 7 years.
Net income was -$155M.
The diluted share count rose 1661% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Spyre Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5M | $5M | $4M | $0 | $0 | $19M | $2M | $886,000 | $0 | $0 |
| Research and development | $18M | $23M | $37M | $65M | $60M | $57M | $59M | $90M | $163M | $172M |
| Selling, general and admin | $8M | $10M | $13M | $16M | $22M | $27M | $29M | $40M | $46M | $48M |
| Operating income | -$22M | -$28M | -$45M | -$80M | -$81M | -$66M | -$85M | -$242M | -$209M | -$210M |
| Pre-tax income | — | — | — | -$78M | -$81M | -$66M | -$84M | -$339M | -$208M | -$155M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $141,000 | -$136,000 | -$26,000 | $51,000 | -$15,000 |
| Net income | -$22M | -$27M | -$44M | -$78M | -$81M | -$66M | -$84M | -$339M | -$208M | -$155M |
| EPS (diluted) | -$55.50 | -$45.00 | -$53.25 | -$61.25 | -$38.00 | -$25.02 | -$24.86 | $13.76 | — | — |
| Diluted shares | 0M | 1M | 1M | 1M | 2M | 3M | 3M | 7M | — | — |
| Operating margin | -473.3% | -531.7% | -1169.3% | — | — | -350.3% | -3640.2% | -27348.0% | — | — |
| Net margin | -468.8% | -523.3% | -1140.6% | — | — | -351.1% | -3598.8% | -38238.1% | — | — |
Balance sheet
Fiscal years, from Spyre Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $64M | $50M | $74M | $72M | $146M | $93M | $56M | $339M | $603M | $756M |
| Total current assets | $66M | $55M | $77M | $75M | $150M | $99M | $62M | $342M | $608M | $778M |
| Property, plant and equipment | $599,000 | $854,000 | $1M | $2M | $6M | $5M | $3M | $0 | — | — |
| Total assets | $67M | $56M | $78M | $83M | $162M | $110M | $71M | $342M | $608M | $778M |
| Total current liabilities | $4M | $6M | $10M | $18M | $16M | $20M | $15M | $32M | $54M | $59M |
| Total liabilities | $4M | $6M | $10M | $23M | $22M | $26M | $21M | $73M | $91M | $63M |
| Shareholders' equity | $63M | $50M | $67M | $60M | $140M | $84M | $50M | $184M | $518M | $715M |
| Net debt | -$48M | -$13M | -$22M | -$19M | -$90M | -$15M | -$35M | -$189M | -$89M | -$86M |
Cash flow
Fiscal years, from Spyre Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$19M | -$25M | -$32M | -$66M | -$76M | -$54M | -$80M | -$100M | -$157M | -$169M |
| Capital spending | $212,000 | $619,000 | $422,000 | $1M | $4M | $573,000 | $38,000 | $0 | $0 | — |
| Free cash flow | -$19M | -$25M | -$33M | -$67M | -$80M | -$54M | -$80M | -$100M | -$157M | — |
| Stock-based compensation | $1M | $2M | $4M | $5M | $6M | $8M | $7M | $26M | $45M | $38M |
| Free cash flow margin | -411.7% | -484.8% | -838.9% | — | — | -289.7% | -3442.8% | -11276.5% | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for SYRE.
Open SYRE in InvestinglyQuestions
What was Spyre Therapeutics's revenue in 2025?
$0 in fiscal 2025, from its 10-K filing.
From Spyre Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.